Responses

Download PDFPDF

Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations
Free
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Rituximab treatment in Wegener's Granulomatosis
    • Karina A Keogh, Pulmonary and Critical Care Medicine
    • Other Contributors:
      • Ulrich Specks

    Dear Editor,

    We read the article by Aries and colleagues with great interest. The authors describe a cohort of 8 patients with refractory Wegener’s granulomatosis, of which 6 had no apparent response to Rituximab. Based on this lack of response and based on the clinical disease manifestations of the patients, the authors conclude that Rituximab may be ineffective in patients with refractory granulomatous disease ma...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Comment on Lack of efficacy of rituximab in refractory wegener's granulomatosis

    Dear Editor

    Aries et al. demonstrate in their study, the lack of response of granulomatous disease in Wegener's granulomatosis to rituximab. From my reading of the paper, this agent was given every fourth week. This is not how this agent is usually prescribed, ie usually given as weekly pulses for four weeks. Despite this, Bcell numbers were depleted in the peripheral blood, though I would doubt at this low dose...

    Show More
    Conflict of Interest:
    None declared.